[go: up one dir, main page]

WO2013086260A3 - Thérapie d'association pour le traitement du cancer - Google Patents

Thérapie d'association pour le traitement du cancer Download PDF

Info

Publication number
WO2013086260A3
WO2013086260A3 PCT/US2012/068351 US2012068351W WO2013086260A3 WO 2013086260 A3 WO2013086260 A3 WO 2013086260A3 US 2012068351 W US2012068351 W US 2012068351W WO 2013086260 A3 WO2013086260 A3 WO 2013086260A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
combination therapy
mapk pathway
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/068351
Other languages
English (en)
Other versions
WO2013086260A2 (fr
WO2013086260A4 (fr
Inventor
Timothy C. Hoey
Christopher L. MURRIEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomed Pharmaceuticals Inc
Original Assignee
Oncomed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals Inc filed Critical Oncomed Pharmaceuticals Inc
Priority to US14/362,991 priority Critical patent/US20150132301A1/en
Priority to EP12854925.0A priority patent/EP2788378A4/fr
Priority to JP2014546103A priority patent/JP2015502958A/ja
Publication of WO2013086260A2 publication Critical patent/WO2013086260A2/fr
Publication of WO2013086260A3 publication Critical patent/WO2013086260A3/fr
Publication of WO2013086260A4 publication Critical patent/WO2013086260A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés comprenant la thérapie d'association pour le traitement du cancer. En particulier, la présente invention concerne des inhibiteurs de la voie Wnt en association avec des inhibiteurs de la voie MAPK pour le traitement de cancer et d'autres maladies.
PCT/US2012/068351 2011-12-09 2012-12-07 Thérapie d'association pour le traitement du cancer Ceased WO2013086260A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/362,991 US20150132301A1 (en) 2011-12-09 2012-12-07 Combination Therapy for Treatment of Cancer
EP12854925.0A EP2788378A4 (fr) 2011-12-09 2012-12-07 Thérapie d'association pour le traitement du cancer
JP2014546103A JP2015502958A (ja) 2011-12-09 2012-12-07 がんの処置のための併用療法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161568844P 2011-12-09 2011-12-09
US61/568,844 2011-12-09
US201261698030P 2012-09-07 2012-09-07
US61/698,030 2012-09-07

Publications (3)

Publication Number Publication Date
WO2013086260A2 WO2013086260A2 (fr) 2013-06-13
WO2013086260A3 true WO2013086260A3 (fr) 2013-07-25
WO2013086260A4 WO2013086260A4 (fr) 2013-09-19

Family

ID=48575059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/068351 Ceased WO2013086260A2 (fr) 2011-12-09 2012-12-07 Thérapie d'association pour le traitement du cancer

Country Status (4)

Country Link
US (1) US20150132301A1 (fr)
EP (1) EP2788378A4 (fr)
JP (1) JP2015502958A (fr)
WO (1) WO2013086260A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3281640A1 (fr) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
WO2015009851A1 (fr) * 2013-07-16 2015-01-22 Icahn School Of Medicine At Mount Sinai Procédés permettant de traiter le cancer chez des sujets atteints d'un dysfonctionnement métabolique
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
TW201610168A (zh) * 2013-12-02 2016-03-16 安可美德藥物股份有限公司 與Ｗｎｔ途徑抑制劑有關之預測性生物標記之鑑別
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
EP2975047A1 (fr) * 2014-07-18 2016-01-20 Université de Lausanne Polypeptides Wnt7a et leur utilisation
WO2017040666A2 (fr) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Polythérapie pour le traitement d'une maladie
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
CN110573878A (zh) * 2017-03-16 2019-12-13 小利兰·斯坦福大学托管委员会 用于kras阳性癌症的诊断和治疗方法
CN107441045B (zh) * 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
EP4378478A4 (fr) * 2021-07-27 2025-11-12 Toray Industries Médicament pour le traitement et/ou la prévention du cancer
US20230383360A1 (en) * 2021-12-16 2023-11-30 D2G Oncology, Inc. Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214186A1 (en) * 2001-04-05 2004-10-28 David Engelberg Method for identifying constitutively active mutants of mitogen activated protein kinase (mapk) and uses thereof
US20100104574A1 (en) * 2008-09-26 2010-04-29 Gurney Austin L Frizzled-Binding Agents and Uses Thereof
WO2011088123A2 (fr) * 2010-01-12 2011-07-21 Oncomed Pharmaceuticals, Inc. Antagonistes wnt et procédés de traitement et de criblage
WO2011101409A1 (fr) * 2010-02-19 2011-08-25 Novartis Ag Composés de la pyrrolopyrimidine utilisés en tant qu'inhibiteurs des cdk4/6
WO2011112678A1 (fr) * 2010-03-09 2011-09-15 Dana-Farber Cancer Institute, Inc. Procédés de diagnostic et de traitement du cancer chez des patients ayant ou développant une résistance à une première thérapie anticancéreuse

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018233A1 (fr) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Dérivés de n-(arylamino)arylsulfonamide comprenant des polymorphes en tant qu'inhibiteurs de mek ainsi que compositions, procédés d'utilisation et procédés de préparation de ceux-ci
BRPI0707671A2 (pt) * 2006-02-09 2011-05-10 Daiichi Sankyo Co Ltd composiÇço farmacÊutica anti-cÂncer
CN101541977A (zh) * 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
WO2008115890A2 (fr) * 2007-03-19 2008-09-25 Takeda Pharmaceutical Company Limited Inhibiteurs de mapk/erk kinase
CL2008001373A1 (es) * 2007-05-11 2008-11-21 Bayer Schering Pharma Ag Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
JP5580735B2 (ja) * 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
CA2693232A1 (fr) * 2007-07-18 2009-01-22 Novartis Ag Composes heteroaryliques bicycliques et leur utilisation comme inhibiteurs de kinase
EP2175885B1 (fr) * 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
BRPI0820504A2 (pt) * 2007-11-05 2015-06-16 Novartis Ag Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt
ES2456966T3 (es) * 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
CN103948600A (zh) * 2009-03-11 2014-07-30 阿迪生物科学公司 用于治疗特定癌症的包含rdea119/bay869766的药物组合
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
NZ602700A (en) * 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
JP5941069B2 (ja) * 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214186A1 (en) * 2001-04-05 2004-10-28 David Engelberg Method for identifying constitutively active mutants of mitogen activated protein kinase (mapk) and uses thereof
US20100104574A1 (en) * 2008-09-26 2010-04-29 Gurney Austin L Frizzled-Binding Agents and Uses Thereof
WO2011088123A2 (fr) * 2010-01-12 2011-07-21 Oncomed Pharmaceuticals, Inc. Antagonistes wnt et procédés de traitement et de criblage
WO2011101409A1 (fr) * 2010-02-19 2011-08-25 Novartis Ag Composés de la pyrrolopyrimidine utilisés en tant qu'inhibiteurs des cdk4/6
WO2011112678A1 (fr) * 2010-03-09 2011-09-15 Dana-Farber Cancer Institute, Inc. Procédés de diagnostic et de traitement du cancer chez des patients ayant ou développant une résistance à une première thérapie anticancéreuse

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2788378A4 *
WEEKES ET AL.: "Safety, Pharmacokinetics, and Pharmacodynamics Results from a Phase I Trial of BAY 86-9766 (RDEA119), a MEK Inhibitor, in Patients with Advanced Cancer.", 2011 ASCO ANNUAL MEETING, 3 June 2011 (2011-06-03), pages 1 - 16, XP008173636 *

Also Published As

Publication number Publication date
EP2788378A4 (fr) 2015-09-09
WO2013086260A2 (fr) 2013-06-13
US20150132301A1 (en) 2015-05-14
WO2013086260A4 (fr) 2013-09-19
JP2015502958A (ja) 2015-01-29
EP2788378A2 (fr) 2014-10-15

Similar Documents

Publication Publication Date Title
WO2013086260A3 (fr) Thérapie d'association pour le traitement du cancer
ZA202208792B (en) Methods of treating and preventing graft versus host disease
WO2014089241A3 (fr) Profilage moléculaire pour cancer
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
PH12018500322A1 (en) Methods of treating cancer patients with farnesyltransferase inhibitors
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
WO2013192274A3 (fr) Méthodes de diagnostic et de traitement chez des sujets atteints d'une résistance à une thérapie anticancéreuse ou présentant un risque de développer une telle résistance
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EP3082800A4 (fr) Traitement du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la raf
WO2012092336A3 (fr) Profilage moléculaire pour le cancer
HK1232119A1 (zh) 用於治疗癌症的检查点抑制剂和治疗剂的组合
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
WO2013024282A3 (fr) Composés et leurs utilisations
HK1219421A1 (zh) 激酶抑制剂的组合及其用途
HK1211085A1 (zh) 治療缺鐵性貧血的方法
PH12013501894A1 (en) Human tissue factor antibody and uses thereof
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
WO2014080286A3 (fr) Méthodes et compositions pour le traitement de la sclérose en plaques et de troubles associés
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
WO2013037943A8 (fr) Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf
HK1220520A1 (zh) 预测对疼痛治疗的应答的方法和系统
WO2014165713A3 (fr) Traitement des affections inflammatoires par modulation de l'activité hyaluronane et hyaluronidase
WO2015156674A3 (fr) Méthode de traitement du cancer
WO2014059326A3 (fr) Procédés d'identification de composés pour traiter la dépression et d'autres maladies associées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12854925

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14362991

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014546103

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012854925

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012854925

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12854925

Country of ref document: EP

Kind code of ref document: A2